Regeneron Gets Federal Manufacturing Contract for Covid-19 Cocktail
July 07 2020 - 7:44AM
Dow Jones News
By Matt Grossman
Regeneron Pharmaceuticals Inc. has received a $450 million
contract from the federal government's Covid-19 vaccine project to
manufacture its investigational double-antibody cocktail to treat
and prevent the disease, the company said Tuesday.
The contract, from the Operation Warp Speed initiative, will
fund manufacturing of the cocktail, REGN-COV2, as the compound is
tested in two Phase 2/3 clinical trials. The cocktail is being
evaluated as both a treatment for the disease and a preventative
measure against it.
The agreement is for a fixed number of bulk lots of the
cocktail, which are set to be complete this autumn. The results of
the drug trials will determine how many doses Regeneron's
production will comprise as varying potential dose sizes are
evaluated. The planned production will likely amount to between
70,000 and 300,000 treatment doses or between 420,000 and 1.3
million prevention doses, the company said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 07, 2020 07:29 ET (11:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
